Stable Cell Line Generation Services
High-quality · Rapid turnaround · Fully validated stable clones
Overview
ICDMO provides comprehensive, high-quality stable cell line generation services designed to accelerate protein expression research, gene function studies, and precision genome editing programmes. Our platform supports over 150 validated host cell lines—including HEK293, CHO-K1, Jurkat, MCF-7, HT-29, and 3T3—delivering reproducible, project-ready stable clones tailored to every client's scientific and bioproduction objectives.
Combining optimised expression vectors, high-throughput clone screening, and animal-component-free protocols, our team generates stable cell lines with consistent transgene expression and robust genetic stability across extended passaging. Every project is assigned a dedicated project manager who oversees timelines, troubleshooting, and data delivery from initial design through to certified material release.
Whether you need constitutive overexpression, inducible regulation, CRISPR-mediated knockout or knock-in, or long-term RNA interference, ICDMO has the expertise and infrastructure to support your project at every stage—from construct design to fully characterised, delivery-ready stable clones.
Highlights
Comprehensive Solutions for Stable Cell Line Generation
Our service portfolio spans the full spectrum of stable cell line engineering—from plasmid-based and lentiviral overexpression to precision genome editing via CRISPR/Cas9. We routinely work with primary cells, iPSC-derived lines, suspension cultures, and difficult-to-transfect cell types, providing a solution for virtually every research challenge. All constructs are sequence-verified prior to delivery, and every stable line undergoes multi-passage stability testing to confirm expression fidelity over time.
Platform Expertise and Process Optimisation
01
Vector Design & Optimisation
- Codon optimisation for enhanced expression
- Promoter selection matched to host cell
- Incorporation of WPRE and other stabilising elements
- Custom multi-cistronic constructs available
02
Cell Line Development & Screening
- Systematic host cell evaluation
- Transfection condition optimisation
- High-throughput FACS or antibiotic selection
- Limiting dilution monoclonal isolation
03
Advanced Genome Editing
- CRISPR/Cas9 knockout — biallelic verified
- HDR-mediated precise knock-in
- Custom shRNA / miRNA interference
- Off-target analysis on request
Core Services
Case Studies & Research Outcomes
The following representative publications illustrate how ICDMO-generated stable cell lines have advanced translational research across oncology, endocrinology, and infectious disease. All cell line models were custom-engineered and fully validated prior to experimental use.
Case Study 1 — Immuno-oncology: CAR-T Efficacy Modelling
Researchers required a luminescent tumour model to track CAR-T cell anti-tumour activity in vivo. ICDMO engineered Luc⁺ Nalm6 stable lines by lentiviral transduction, enabling real-time bioluminescence imaging (BLI) of tumour burden following tail-vein engraftment into NSG mice. The stable bioluminescent signal allowed longitudinal quantification of CAR-T therapeutic efficacy without animal sacrifice at each time point.
Cell Line Used: Lentiviral Stable Cell Line Service
Figure 1. BLI tracking of Luc⁺ Nalm6 tumour growth and regression following CAR-T cell infusion in NSG mice. 1 × 10⁶ cells were engrafted per animal.
Case Study 2 — Endocrinology: GPCR Signalling in Reproductive Disease
To investigate the modulatory role of Frizzled-3 (FZD3) in follicle-stimulating hormone (FSH)-mediated steroidogenesis, the research team required stable HEK293 lines co-expressing FSHR and FZD3 at defined levels. ICDMO generated multi-transgenic stable lines using sequential selection, enabling co- immunoprecipitation and cAMP signalling assays that revealed FZD3's inhibitory role in FSH-stimulated steroid biosynthesis—providing mechanistic insight into polycystic ovary syndrome (PCOS) pathology.
Cell Line Used: GPCR Stable Cell Line Development
Figure 2. cAMP accumulation and steroidogenesis assays in FSHR/FZD3 co-expressing HEK293 stable lines demonstrating FZD3-mediated inhibition.
Case Study 3 — Virology: SARS-CoV-2 Receptor-Binding Assay Platform
A biosafe cell-based platform was required to compare receptor-binding kinetics of SARS-CoV-2 and SARS spike proteins without handling live virus. ICDMO generated ACE2 and TMPRSS2 dual-expressing A549 stable lines, which enabled quantitative binding assays using gold nanourchin-conjugated spike proteins. The stable expression platform provided reproducible surface receptor densities, ensuring data comparability across experimental batches and assay formats.
Cell Line Used: Multi-Transgene Stable Cell Line Service
Figure 3. Receptor-binding comparison between SARS-CoV-2 and SARS spike proteins using gold nanourchin conjugates on ACE2/TMPRSS2-expressing A549 stable lines.
Service Support
Customised Construction Methods
| Service | Details | Methods |
|---|---|---|
| Gene Overexpression Stable Cell Lines | Constitutive expression: single or multi-gene cassettes | Lipofectamine™ Transfection, Electroporation, Lentiviral Transduction |
| Inducible Expression Stable Cell Lines | Tet-On / Tet-Off regulated expression system | Lipofectamine™ Transfection, Electroporation, Lentiviral Transduction |
| Gene Knockdown Stable Cell Lines | shRNA-mediated sustained gene silencing | Lipofectamine™ Transfection, Electroporation, Lentiviral Transduction |
| miRNA Overexpression Stable Cell Lines | Stable delivery of miRNA precursor sequences | Lipofectamine™ Transfection, Electroporation, Lentiviral Transduction |
| Gene Knock-out Stable Cell Lines | CRISPR/Cas9-mediated complete gene disruption | CRISPR/Cas9 gene editing system |
| Gene Knock-in Stable Cell Lines | Precision sequence insertion via HDR or NHEJ | Homology-Directed Repair (HDR) / Non-Homologous End Joining (NHEJ) |
Quality Control
- Genetic Validation: Sequence verification and digital-droplet PCR copy-number analysis confirm correct integration and transgene integrity in every delivered clone.
- Expression Validation: Target RNA is quantified by RT-qPCR; protein expression level and molecular weight are confirmed by Western blot and/or flow cytometry against project specification.
- Biosafety Certification: All delivered cell lines are certified mycoplasma-free by PCR and/or enzymatic assay. Sterility and adventitious agent testing are performed as standard.
Technical Workflow
1
Precise selection of expression vector and gene target
2
Development of a tailored engineering strategy
3
Assembly of expression or knockdown constructs
4
Large-scale vector production with quality verification
5
Stable clone establishment through stringent selection
6
Comprehensive molecular validation — Western blot, PCR, sequencing
7
Ongoing technical guidance and troubleshooting support
8
Delivery of verified clones with full protocols and data package
What We Need From You
▸Target gene or transgene with species, isoform and the exact sequence change or expression outcome required
▸Host cell line and delivery method available to you, since both constrain guide performance and construct design
▸Whether the gene is essential, and whether inducible or conditional control is needed
▸Screening and validation capacity, which determines how many clones and constructs the design should assume
▸Previous attempts at the locus with what was observed, including guides or constructs that failed
How the Work Is Performed
▸Locus analysis: isoform structure, constitutive exons, regulatory elements and repeat content
▸Guide design with on-target activity scoring and genome-wide off-target assessment
▸Donor and cassette design with homology arms, silent mutations and regulatory element selection
▸Expression strategy design, including promoter strength, inducible architecture and tag placement
▸Knockdown sequence design with transcriptome-wide seed screening and rescue construct design
▸Screening strategy design: junction PCR, amplicon sequencing, copy number and functional confirmation
What You Receive
▸Ranked guide, donor, cassette or knockdown designs with the rationale for each
▸Genome-wide off-target assessment and the sites worth checking empirically
▸Annotated construct maps ready for synthesis, with every deliberate change documented
▸Clone screening plan with primers and the assays that distinguish correct from incorrect events
▸Realistic expectations for editing efficiency and clone numbers, stated as ranges rather than single figures
Interpretation and Limitations
Predicted guide efficiency correlates with measured activity but does not replace testing, and observed editing rates vary substantially with cell type, delivery and chromatin state. Computational off-target prediction covers sequence-similar sites only; empirical profiling is required before any specificity claim. Expression levels and long-term stability of engineered lines are established experimentally. Editing, cloning, clone isolation and screening are performed by your laboratory or a partner.
Questions We Are Asked Before Scoping
How many guides or constructs should we test?
Three to five guides, or three to six expression constructs, tested in parallel. Prediction narrows the field; it does not identify the single best candidate reliably enough to bet on one.
Can you design conditional systems?
Yes — inducible, degron-based and conditional knockout strategies, including the leakiness assessment that determines whether an inducible system will actually behave as intended.
Do you generate the cell lines?
No. ICDMO delivers the design and the screening strategy; line generation is performed by your team or a qualified partner, and we help interpret the sequencing and validation data that comes back.
ICDMO brings together multidisciplinary expertise in molecular biology, cell engineering, and process development to deliver stable cell lines that meet the highest standards of reproducibility and genetic integrity. Our team has successfully completed projects for clients in academic research, biotech, and pharmaceutical discovery worldwide.
Ready to discuss your project? Our scientific team is available to consult on experimental design, cell line selection, and delivery timelines. Request a no-obligation quote today.